cv 3988 has been researched along with thromboxane b2 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeuchi, H; Mason, AD; Pruitt, BA; Sakano, T; Sanchez, J | 1 |
| Adachi, M; Imai, T; Kamiya, I; Kobayashi, H; Nishikata, H; Okazawa, A; Satoh, H; Takahashi, T; Yamaguchi, H | 1 |
| Robertson, DN; Smith, GM | 1 |
| Okano, S; Tagawa, M; Urakawa, N | 1 |
4 other study(ies) available for cv 3988 and thromboxane b2
| Article | Year |
|---|---|
The effects of platelet-activating factor (PAF) and a PAF antagonist (CV-3988) on smoke inhalation injury in an ovine model.
Topics: Animals; Dinoprostone; Lipid Peroxidation; Male; Malondialdehyde; Phospholipid Ethers; Platelet Activating Factor; Platelet Count; Sheep; Smoke Inhalation Injury; Thromboxane B2; Time Factors | 1992 |
[The effect of a specific antagonist of PAF (CV-3988) on airway hyperresponsiveness induced by ozone exposure in beagles].
Topics: Animals; Bronchi; Dogs; Female; Methacholine Chloride; Methacholine Compounds; Ozone; Phospholipid Ethers; Platelet Activating Factor; Thiazoles; Thromboxane B2 | 1987 |
CV3988 inhibits in vivo platelet aggregation induced by PAF-acether and collagen.
Topics: Animals; Blood Pressure; Collagen; Male; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation; Platelet Count; Rabbits; Rats; Species Specificity; Thiazoles; Thromboxane B2; Time Factors | 1986 |
Effect of platelet activating factor antagonist (CV-3988) on 6-keto-PGF1 alpha and thromboxane B2 in dogs with experimental endotoxin-induced shock.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Dog Diseases; Dogs; Hemodynamics; Phospholipid Ethers; Platelet Activating Factor; Shock, Septic; Thromboxane B2 | 1995 |